2269:HKG
우시바이오로직스
HK$48.20
arrow_downward
-0.90%(-0.44) 1D
10월 16일, 오후 4시 8분 14초 GMT+8 · HKD
search
모든 종목 코드
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_auto2269의 주요 통계 생성 중...
시가
HK$49.98
고가
HK$50.85
저가
HK$45.82
시가총액
1984.28억
평균 거래량
3042.48만
거래량
5518.23만
주가수익률
34.48
52주 최고가
HK$58.00
52주 최저가
HK$28.48
EPS
HK$1.40
유통 주식수
12.25억
직원 수
1만
시가
HK$49.98
고가
HK$50.85
저가
HK$45.82
시가총액
1984.28억
평균 거래량
3042.48만
거래량
5518.23만
주가수익률
34.48
52주 최고가
HK$58.00
52주 최저가
HK$28.48
EPS
HK$1.40
유통 주식수
12.25억
직원 수
1만
뉴스 기사
웹 소스 및 뉴스 파트너 제공
블루밍비트
·
45분 전
뉴욕증시, 혼조세로 전환…나스닥 1.04%↓
연합인포맥스
·
11시간 전
'스페이스X로 대박'…하버드대 기금 수익률, S&P 500지수보다 높은 27%
프로필
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
우시바이오로직스에 관한 정보